## UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. ARMY144

Total Pages in this Submission 115

### TO THE COMMISSIONER FOR PATENTS

**Mail Stop Patent Application** 

P.O. Box 1450 Alexandria, VA 22313-1450	
Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent ap	oplication for an
invention entitled: Ebola Virion Proteins Expressed from Venezuelan Equine Encephalitis Virus Replicons	
Ebola Virion Proteins Expressed from Venezuelan Equine Encephantis Virus Replicons	
<u> </u>	500
	93
and invented by:	
Hart, Mary Kate Wilson, Julie A	9/0
Smith, Jonathan F. Schmaljohn, Alan L.	8 =
Pushko, Peter	``
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:	
☑ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:	09/337,946(6-22-99)
Which is a:	
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:	
Which is a:	
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:	•
Footboard and	
Enclosed are:  Application Elements	•
	٠.
1. 🗵 Filing fee as calculated and transmitted as described below	
2. Specification having 64 pages and including the following:	
	٠
a. 🗵 Descriptive Title of the Invention	
b.   Cross References to Related Applications (if applicable)	•
c.   Statement Regarding Federally-sponsored Research/Development (if applicable)	
d. 🗵 Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix	
e. 🗵 Background of the Invention	
f. 🗵 Brief Summary of the Invention	
g 🗵 Brief Description of the Drawings (if filed)	
h. 🗵 Detailed Description	
i. ⊠ Claim(s) as Classified Below	
j. 🛛 Abstract of the Disclosure	

# UTILITY PATENT APPLICATION TRANSMITTAL (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. ARMY144

Total Pages in this Submission 115

3.	$\boxtimes$	Drawing(s) (when necessary as prescribed by 35 USC 113)
	a.	Formal Number of Sheets 6
	b.	□ Informal Number of Sheets
4.	X	Oath or Declaration
	a.	☐ Newly executed (original or copy) ☐ Unexecuted
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
	C.	☐ With Power of Attorney ☐ Without Power of Attorney
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5.	×	Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
<b>6</b> .		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7.		Application Data Sheet (See 37 CFR 1.76)
8.	X	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
	a.	☐ Computer Readable Form (CRF)
	b.	Specification Sequence Listing on:
		i.   CD-ROM or CD-R (2 copies); or
		ii. 🔀 Paper
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy
		Accompanying Application Parts
9.		Assignment Papers (cover sheet & document(s))
10.		37 CFR 3.73(B) Statement (when there is an assignee)
11.		English Translation Document (if applicable)
12.	$\boxtimes$	Information Disclosure Statement/PTO-1449   Copies of IDS Citations
13. ·		Preliminary Amendment
14.	X	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	X	Certificate of Mailing
		☐ First Class ☑ Express Mail (Specify Label No.): EU473900403US

Application Elements (C ntinu d)

# UTILITY PATENT APPLICATION TRANSMITTAL (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. ARMY144

Total Pages in this Submission 115

Acc mpanying Applicati n Parts (Continued)

17.	X	Additional Enclosures (please identify below):
		Claim for Priority; Statement Under Rule 98(d)
		·
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
3.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under
8.	<u> </u>	Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing

# UTILITY PATENT APPLICATION TRANSMITTAL (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

Total Pages in this Submission 115

#### Fee Calculation and Transmittal

#### **CLAIMS AS FILED** Fee Rate #Allowed #Extra For #Filed \$0.00 \$18.00 0 - 20 = **Total Claims** \$0.00 \$86.00 3 - 3 = Indep. Claims \$0.00 Multiple Dependent Claims (check if applicable) \$770.00 **BASIC FEE** \$0.00 OTHER FEE (specify purpose) **TOTAL FILING FEE** \$770.00 to cover the filing fee is enclosed. ☐ A check in the amount of ☑ The Director is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. ☐ Charge the amount of \$770.00 as filing fee. Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance pursuant to 37 C.F.R. 1.311(b). Signature Marlana Titus, Reg. No. 35,843 for Elizabeth Arwine, Reg. No. 45,867 Dated: October 29, 2003 U.S. Army Medical Research and Materiel Command **504 Scott Street** Ft. Detrick, MD 21702-5012 (301) 977-7227 or (301) 924-9500

CC:

or (301) 619-7808

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of HART et al.

Appln. No: not yet known

Cont. of Appln. No.: 09/337,946

Group Art Unit: 1648

Filed: October 29, 2003

Examiner: D. Wortman

Title: EBOLA VIRION PROTEINS EXPRESSED FROM VENEZUELAN EQUINE ENCEPHALITIS VIRUS REPLICONS

October 29, 2003

## COMMUNICATION REGARDING CERTAIN CO-PENDING U.S. APPLICATIONS

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In connection with the above-identified application, Applicants wish to bring to the Examiner's attention the following U.S. co-pending applications, sharing common ownership with the subject application:

Serial No.: 09/650,086 (filed August 29, 2000) Serial No: 60/151,505 (filed August 30, 1999) Serial No.: 09/781,124 (filed February 9, 2001) Serial No: 60/182,066 (filed February 11, 2000)

Marlana K. Titus, Reg. No. 35,843

Elizabeth Arwine, Reg. No. 45,867

Attorney for Applicants

U.S. Army Medical Research and Materiel Command

504 Scott St., ATTN: MCMR-JA Fort Detrick, MD 21702-5012

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Hart et al.

Appln. No: not yet known

Cont. of Appln. No.: 09/337,946

Group Art Unit: 1648

Filed: October 29, 2003

Examiner: D. Wortman

Title: EBOLA VIRION PROTEINS EXPRESSED FROM VENEZUELAN EQUINE ENCEPHALITIS VIRUS REPLICONS

### CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 C.F.R. 1.10)

I hereby certify that the following correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, on October 29, 2003:

(1) Transmittal sheets for U.S. application (large entity) (4 pages, in duplicate); (2) U.S. utility application (70 pages, including 6 sheets of drawings); (3) Preliminary Amendment (4 pages); (4) Communication Regarding Certain Co-Pending U.S. Applications (1 page); (5) Copy of Declaration from parent application 09/337,946 (2 pages); (6) Information Disclosure Statement (2 pages); (7) PTO-1449 form (4 pages); (8) Statement Pursuant to 37 CFR 1.198(d) (1 page); (9) Claim for priority (1 page); (10) Sequence Listing (paper copy) (18 pages); (11) Statement Accompanying Sequence Listing and Request for Transfer of Computer Readable Form From Parent Application (2 pages); (12) Postcard receipt

Marlana K. Titus

Nash & Titus, LLC

Reg. No. 35,843 3415 Brookeville Road

**Suite 1000** 

Brookeville, MD 20833

(301) 977-7227 or (301)924-9500 or

(301)619-7808

Express Mail Mailing Label Number: ET473900403US